These effects have been in vivo displayed by the use of MSCs, via the increased peripheral lymphocytes amount, the decline in the C-reactive protein, and waning of over-activated cytokine-secreting immune cells (CXCR3 + CD4 + T cells, CXCR3 + CD8 + T cells, and CXCR3 + Natural Killer (NK) cells) into the blood of COVID-19 patients, by mean 4.5 days later the MSCs with intravenous administration [5]. Here, CXCR3 is linked to COVID-19.